On December 28, 2017, the U.S. Food and Drug Administration (FDA) permitted the marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.
Read more via Fda.gov.
On December 28, 2017, the U.S. Food and Drug Administration (FDA) permitted the marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.
Read more via Fda.gov.
